Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland, ranking number two in sales (46.806 billion US$) among the world-wide industry in 2010.

Novartis manufactures such drugs as clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate and (Gleevec / Glivec). Additional agents include cyclosporin (Neoral / Sandimmun), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil), and others.

Renamed to Novartis following an acquisition by Ciba-Geigy, it owns Sandoz, a large manufacturer of generic drugs. The company formerly owned the Gerber Products Company, a major infant and baby products producer, but sold it to Nestlé on 1 September 2007.

Novartis is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).

Read more about NovartisHistory, Collaborative Research, Basel Headquarters Campus Redesign, Research and Development

Other articles related to "novartis":

Ritalin Class Action Lawsuits - Novartis, APA, and CHADD Respond
... A spokesperson for Novartis responded to the Texas suit, "Ritalin has been used safely and effectively in the treatment of millions of ADHD patients for over 40 years, and is ...
List Of Nestlé Brands - As Shareholder
... Nestlé sold 24.8% of Alcon shares to the Swiss pharmaceutical giant Novartis ... In 2010 Nestlé sold another 52% of Alcon to Novartis ... Novartis paid a total of 39.1 bn US$ ...
Public Eye Award - 2007
... Winners Bridgestone (Global), Novartis (Swiss) Positive Award Coop (Switzerland) Bridgestone received the Global Award for the disastrous working conditions at a subsidiary in Liberia ... Novartis received the Swiss Award for the patenting of the cancer drug Imatinib, forcing a halt in production of Indian generics ... The product from Novartis is ten times more expensive than the generics ...
Novartis - Controversies and Criticism - Using The Courts To Prevent British Health Trusts From Switching To Cheaper Alternatives
... According to the BBC, Novartis is using the courts to try and prevent British NHS Trusts switching from using Lucentis at £700 an injection to using rival Avastin at £60 an ...
Paul Herrling
... is the head of corporate research at Novartis and the chairman of board of the Novartis Institute for Tropical Diseases, Singapore since 2002 ... Prior to this, he was the head of Global Research of Novartis Pharma ...